Welcome to a regular roundup of business and medical news from ISAB. Find out how we’re breathing new life into inhalation R&D.

ASTRA ZENECA TO RELEASE NEW RESEARCH FROM PRECISEINHALE AT AIT COPENHAGEN, OCTOBER 26 - 27

AstraZeneca will release data achieved using PreciseInhale in a poster at the Association of Inhalation Toxicologists (AIT) conference. AstraZeneca already began using PreciseInhale in its research in Summer 2017, prior to ISAB’s announcement on Sept 27 that the company had decided to purchase PreciseInhale outright. The AIT poster will show data from the collaboration.


ISAB CSO PER GERDE KEYNOTE SPEAKER AT 6th MEDICON VALLEY SYMPOSIUM, LUND, 11 OCTOBER

Our pioneering CSO Per Gerde will speak on 11 October in Lund, Sweden on CONTROLLED AEROSOL EXPOSURES, at the 6th Medicon Valley Inhalation Symposium.

READ MORE AT: http://www.preciseinhale.com/lab-blog/isab-cso-per-gerde-keynote-speaker-at-6th-medicon-valley-symposium-lund-11-october/

ASTRA ZENECA PURCHASES ENTIRE PRECISEINHALE SYSTEM AND TEST MODULES

On 27 September we announced that AstraZeneca had ordered a complete PreciseInhale system, including all its test modules, in what our CEO Fredrik Sjövall called "a breakthrough order."

READ MORE AT: http://www.inhalation.se/investerare/pressmeddelanden/?pressreleaseld=2681560
UNIVERSITY OF COPENHAGEN INSTALLS PRECISEINHALE FOR RESEARCH INTO NEW INHALED TB THERAPIES

The Department of Pharmacy's Group Leader, Associate Professor Camilla Foged, said: “Installing PreciseInhale in our labs is an important milestone for us. It will allow us to advance our state-of-the-art nanomedicines towards first-in-man studies. The aim of our research is to design a new thermostable, dry powder-based and inhalable vaccine against tuberculosis, and a nanoparticle-based anti-inflammatory formulation for the treatment of chronic obstructive pulmonary disease.”

READ MORE AT: http://www.inhalation.se/investerare/pressmeddelanden/?pressreleaseid=2648221

CHIESI RELEASES POSITIVE TEST RESULTS FOR PRECISEINHALE

A new research paper from Chiesi Farmaceutici S.p.A. (‘Chiesi’) found PreciseInhale performed with “accuracy higher than usual techniques”. Published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery, the paper shows how PreciseInhale gives crucial pharmacokinetic data on new treatments early on in the preclinical phase of development.

READ MORE AT: http://www.inhalation.se/investerare/pressmeddelanden/?pressreleaseid=2654079

To see this Newsletter as a complete PDF go to http://www.inhalation.se/en/news/ or http://www.inhalation.se/nyheter/